Goldman Sachs Downgrades Sage Therapeutics (SAGE) to Neutral, 'stepping to the sidelines as we await more clarity'
Tweet Send to a Friend
(Updated - August 8, 2023 7:41 AM EDT)
Goldman Sachs analyst Salveen Richter downgraded Sage Therapeutics (NASDAQ: SAGE) from ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
Goldman Sachs analyst Salveen Richter downgraded Sage Therapeutics (NASDAQ: SAGE) from ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
